TA200 Hepatitis C - peginterferon alfa and ribavirin: review decision - December 2013 information
History
A list of downloadable documents created during development.
Background information
-
-
TA200 Hepatitis C - peginterferon alfa and ribavirin: Appendix A - decision paper presented to the Institute's Guidance Executive
-
-
TA200 Hepatitis C - peginterferon alfa and ribavirin: review proposal - October 2013 information
-
TA200 Hepatitis C - peginterferon alfa and ribavirin: Appendix A - provisional matrix of stakeholders
-
-
TA200 Hepatitis C - peginterferon alfa and ribavirin: Appendix B - GE Proposal Paper September 2013
-
-
-
Download PDF version
-
Hepatitis C - peginterferon alfa and ribavirin: final appraisal determination
-
Hepatitis C - peginterferon alfa and ribavirin: final appraisal determination information
-
Hepatitis C - peginterferon alfa and ribavirin: final appraisal determination
-
Hepatitis C - peginterferon alfa and ribavirin: final appraisal determination (PDF 212 KB)
-
Hepatitis C - peginterferon alfa and ribavirin: comments on the ACD received from the public through the NICE website
-
-
Hepatitis C - peginterferon alfa and ribavirin: response to consultee, commentator and public comments on the ACD and comments from website consultation
-
-
Hepatitis C - peginterferon alfa and ribavirin: final appraisal determination - consultee and commentator comments on the ACD
-
Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Department of Health
-
-
Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - MSD/Schering Plough
-
-
Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - NHS Quality Improvement Scotland
-
-
Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Roche
-
-
Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Royal College of Nursing
-
-
Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Royal College of Pathologists
-
-
Hepatitis C - peginterferon alfa and ribavirin: consultee and commentator comments on the ACD - Southampton Health Technology Assessment Centre
-
Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation
-
Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation
-
Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation document information
-
Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: evaluation report
-
Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: overview
-
Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: overview (PDF 212 KB)
-
Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: assessment report
-
-
Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: consultee and commentator comments on the assessment report
-
Consultee and commentator comments on the assessment report: Department of Health
-
Consultee and commentator comments on the assessment report: Department of Health (PDF 40 KB)
-
Consultee and commentator comments on the assessment report: NHS Quality Improvement Scotland
-
-
Consultee and commentator comments on the assessment report: Royal College of Nursing
-
Consultee and commentator comments on the assessment report: Royal College of Nursing (PDF 44 KB)
-
Consultee and commentator comments on the assessment report: Royal College of Physicians
-
Consultee and commentator comments on the assessment report: Royal College of Physicians (PDF 96 KB)
-
Consultee and commentator comments on the assessment report: Roche
-
Consultee and commentator comments on the assessment report: Roche (PDF 107 KB)
-
Consultee and commentator comments on the assessment report: Schering-Plough
-
Consultee and commentator comments on the assessment report: Schering-Plough (PDF 359 KB)
-
Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: non-manufacturer submissions
-
Non-manufacturer submissions: Hepatitis C Trust
-
-
Non-manufacturer submissions: Royal College of Physicians and British Society of Gastroenterology
-
-
Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: manufacturer submissions (executive summary only)
-
Manufacturer submissions (executive summary only): Roche
-
Manufacturer submissions (executive summary only): Roche (PDF 65 KB)
-
Manufacturer submissions (executive summary only): Schering-Plough
-
Manufacturer submissions (executive summary only): Schering-Plough (PDF 66 KB)
-
Hepatitis C - peginterferon alfa and ribavirin: appraisal consultation: expert written personal statements
-
Expert written personal statements: Dusheikp
-
-
Expert written personal statements: Gore
-
-
Expert written personal statements: Jose
-
-
Expert written personal statements: Thomas
-
Hepatitis C - peginterferon alfa and ribavirin: assessment report
-
Hepatitis C - peginterferon alfa and ribavirin: assessment report
-
Hepatitis C - peginterferon alfa and ribavirin: assessment report (PDF 1.49 MB)
Hepatitis C - peginterferon alfa and ribavirin: final protocol
-
Hepatitis C - peginterferon alfa and ribavirin: final protocol
-
Hepatitis C - peginterferon alfa and ribavirin: final protocol (PDF 123 KB)
Hepatitis C - peginterferon alfa and ribavirin: response to consultee and commentator comments on provisonal matrix
-
Hepatitis C - peginterferon alfa and ribavirin: response to consultee and commentator comments on provisonal matrix
-
Hepatitis C - peginterferon alfa and ribavirin: response to consultee and commentator comments on the draft scope
-
Hepatitis C - peginterferon alfa and ribavirin: response to consultee and commentator comments on the draft scope
-
Hepatitis C - peginterferon alfa and ribavirin: final scope
-
Hepatitis C - peginterferon alfa and ribavirin: final scope
-
Hepatitis C - peginterferon alfa and ribavirin: final scope (PDF 35 KB)
Hepatitis C - peginterferon alfa and ribavirin: provisional matrix of consultee and commentators
-
Hepatitis C - peginterferon alfa and ribavirin: provisional matrix of consultee and commentators
-
Hepatitis C - peginterferon alfa and ribavirin: draft scope
-
Hepatitis C - peginterferon alfa and ribavirin: draft scope
-
Hepatitis C - peginterferon alfa and ribavirin: draft scope (PDF 45 KB)